Brain Cancer
Celecoxib and temozolomide synergize to reduce glioma tumor growth and vessel density
Published in Cancer Weekly, February 21st, 2006
According to recent research from South Korea, "the purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model."
"After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to 4 treatment groups (group 1, control treatment; group 2, celecoxib [25 mg/kg p.o. every day] alone; group 3, temozolomide [7.5 mg/kg i.p. for 5 days at 2nd week] alone; group 4, a combination of celecoxib and temozolomide)," said S.G. Kang...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-02-21)
More Articles from Cancer Weekly
- Brain Cancer
TWIST is expressed in human gliomas and promotes invasion - Cancer Drugs
Doxorubicin-induced cardiotoxicity could be prevented by melatonin - Colorectal Metastases
Recent chemotherapy reduced sensitivity of FDG-PET in detecting colorectal metastases - Lung Cancer
JNK activation required for gemcitabine's cytotoxic effect in lung cancer - Pituitary Tumors
Mimecan gene expression used as a marker for diagnosing pituitary tumors - Acute Myeloid Leukemia
Modified conventional protocol for childhood AML well tolerated - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
